Effect of ivabradine on heart rate, functional capacity and pulmonary artery pressure in patients of COPD with cor pulmonale.


Journal

Indian heart journal
ISSN: 2213-3763
Titre abrégé: Indian Heart J
Pays: India
ID NLM: 0374675

Informations de publication

Date de publication:
Historique:
received: 16 09 2020
revised: 14 01 2021
accepted: 23 03 2021
entrez: 22 6 2021
pubmed: 23 6 2021
medline: 21 10 2021
Statut: ppublish

Résumé

We studied the effects of heart rate reduction by ivabradine to the ongoing therapy in patients with chronic obstructive pulmonary disease (COPD) and cor pulmonale.100 patients of COPD with cor pulmonale with sinus heart rate ≥ 90 bpm were randomly assigned to either ivabradine 5 mg twice daily (50 patients) or placebo (50 patients) alongwith standard therapy. Assessment was done at baseline and after 6 months which included 6 min walk test (6MWT), dyspnea scoring by modified borg scale, Lung function test by forced expiratory volume in 1 s (FEV1) and pulmonary artery systolic pressure (PASP) by echocardiogram. The drug group showed a significant reduction in heart rate from 95.1 ± 8.2 bpm to 71.1 ± 6.2 bpm (p < 0.001). This group also showed significant improvement in 6-min walk distance and dyspnea on modified Borg scale (p < 0.001) at 6 months follow up. However no significant difference was found between both groups regarding PASP or FEV1 at 6 months.

Identifiants

pubmed: 34154759
pii: S0019-4832(21)00067-5
doi: 10.1016/j.ihj.2021.03.009
pmc: PMC8322798
pii:
doi:

Substances chimiques

Ivabradine 3H48L0LPZQ

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

369-371

Informations de copyright

Copyright © 2021 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.

Références

Kardiologiia. 2012;52(2):41-6
pubmed: 22792738
Eur Respir J. 2013 Aug;42(2):341-9
pubmed: 23143550
Clin Med (Lond). 2016 Oct;16(5):419-422
pubmed: 27697801
Br J Clin Pharmacol. 2008 Jul;66(1):96-101
pubmed: 18341671
Circulation. 2003 Feb 18;107(6):817-23
pubmed: 12591750
J Card Fail. 2014 May;20(5):373-5
pubmed: 24556029
J Cardiol. 1995 Dec;26(6):357-66
pubmed: 8558414
J Clin Pharmacol. 2008 May;48(5):538-46
pubmed: 18353997
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
Circulation. 1992 Jul;86(1):12-21
pubmed: 1617764
Am J Physiol Heart Circ Physiol. 2018 May 1;314(5):H889-H891
pubmed: 29351475
Chest. 2005 Jun;127(6):2057-63
pubmed: 15947320
Med Sci Sports Exerc. 1982;14(5):377-81
pubmed: 7154893
Lancet. 2010 Sep 11;376(9744):875-85
pubmed: 20801500
Lancet. 2010 Sep 11;376(9744):886-94
pubmed: 20801495

Auteurs

Mohammad Kaleem (M)

Department of Cardiology, Institute of Medical Sciences, BHU, Varanasi, India.

Abhishek Kaushley (A)

Department of Cardiology, Institute of Medical Sciences, BHU, Varanasi, India.

Vikas Agrawal (V)

Department of Cardiology, Institute of Medical Sciences, BHU, Varanasi, India. Electronic address: vikky25@yahoo.com.

T B Singh (TB)

Division of Biostatistics, Department of Community Medicine, Institute of Medical Sciences, BHU, Varanasi, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH